Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPC vs GP with Nimotuzumab and Toripalimab in LANPC
NCT06561763Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2024
- Primary completion
- Aug 2028
- Modality
- Polymer-based Nanoparticles, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
01
Overview
A Phase 3 trial of nab-paclitaxel, capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
nab-paclitaxelcapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06561763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06561763.